Usage Examples
- It is a novel excipient with no precedent by the oral route, so it needs its own nonclinical safety package.
- Every excipient lot gets a specific identity test in house before the quality unit releases it.
- Excipient compatibility screening flagged a Maillard reaction between the lactose and the amine API.
What is Excipient?
An excipient is any component of a drug product other than the active ingredient: the binders, diluents, buffers, coatings and preservatives that carry, stabilize or deliver the drug without pharmacological activity of their own.
Excipients exist because an active ingredient is almost never deliverable on its own. A milligram-scale dose has to be given mass, held together, released at the right rate in the right place, protected from moisture and oxygen, and kept stable across its shelf life. Excipients do that work, and each one carries the full component-control burden of CGMP.
Excipients span everything intentionally added to a formulation other than the active ingredient: diluents, binders, disintegrants, lubricants, buffers, solubilizers, preservatives, colorants and coatings. 21 CFR 210.3(b)(8) defines the category purely by exclusion, as any component other than an active ingredient. Outside the boundary sit container closure materials, and degradants, leachables and residual solvents, which are unintended impurities rather than excipients.
Excipients are controlled in practice through the CGMP component chapter. Each lot needs a written receipt, sampling and testing procedure, quarantine until the quality unit releases it, and at least one specific identity test run in house, even when a supplier certificate of analysis is accepted. In the submission, excipients appear in the drug product composition table with function, quality grade and amount per unit.
Not to be confused with
- Active pharmaceutical ingredient (API)
- the API is the component intended to furnish pharmacological activity or other direct effect. The classification turns on that intent, so everything else in the formulation lands on the excipient side by default, not by a separate test.
- Inactive ingredient
- "inactive ingredient" is FDA's regulatory term of art in 21 CFR 210.3(b)(8) and in labelling; "excipient" is the pharmacopoeial and industry word. Same substances, two vocabularies, and FDA correspondence will use the former.
- Component
- component is the wider CGMP term. 21 CFR 210.3(b)(3) covers "any ingredient intended for use in the manufacture of a drug product, including those that may not appear in such drug product", so processing aids are components without being excipients.
- Impurity
- impurities are unintended: degradants, residual solvents, leachables. Excipients are deliberately added and specified. An excipient that degrades generates an impurity; it does not become one.
The obligations sit in the component-control chapter of the finished-pharmaceutical CGMPs, and they apply to every excipient lot, not just the ones you consider risky.
What you must do
- 1Maintain and follow written procedures covering receipt, identification, storage, handling, sampling, testing and approval or rejection of every excipient lot21 CFR 211.80(a)
- 2Withhold each excipient lot from use until it has been sampled, tested or examined and released for use by the quality control unit21 CFR 211.84(a)
- 3Conduct at least one test to verify the identity of each excipient, using the specific identity test where one exists21 CFR 211.84(d)(1)
- 4Test each excipient for conformity with written purity, strength and quality specifications, or accept a supplier report of analysis only while performing a specific identity test in house and validating the supplier's results at appropriate intervals21 CFR 211.84(d)(2)
- 5Classify every formulation component correctly, since anything that is not an active ingredient is an inactive ingredient by definition and inherits the full set of component controls21 CFR 210.3(b)(8)
Common mistakes
Reading "inactive" as "no safety work required"
Inactivity is a pharmacological classification, not a safety clearance. An excipient used outside precedented human exposure for the intended route, dose and duration needs its own nonclinical justification. Discovering that at a pre-NDA meeting costs a reformulation cycle and the stability data that goes with it.
Accepting the supplier's certificate of analysis and stopping there
21 CFR 211.84(d)(2) allows a supplier report only if you still run a specific identity test yourself and periodically validate that supplier's results. A COA on file with no in-house identity test and no supplier qualification is a direct violation, not a paperwork shortcut, and it puts every lot released on that basis in scope.
Treating an excipient grade or supplier swap as a like-for-like change
Particle size, viscosity grade and source change dissolution, content uniformity and stability even when the chemical name is identical. Skipping the comparability assessment means the release decision rests on data that no longer describes the material, and the gap usually surfaces during a stability excursion rather than at changeover.
When This Matters
- It is a novel excipient with no precedent by the oral route, so it needs its own nonclinical safety package.
- Every excipient lot gets a specific identity test in house before the quality unit releases it.
- Excipient compatibility screening flagged a Maillard reaction between the lactose and the amine API.
Frequently Asked Questions
An excipient is pharmacologically inactive at the amount used, but it is not inert. Excipients change dissolution, bioavailability, stability and tolerability. 21 CFR 210.3(b)(8) classifies them purely by exclusion, as any component other than an active ingredient, and that classification says nothing about biological effect.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
Related Regulatory Intelligence
Related Actions
Sources & References
- 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General
- 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals
- FDA Current Good Manufacturing Practice (CGMP) Regulations
- ICH Quality Guidelines (Q8(R2) Pharmaceutical Development)
